AFP and hepatocellular carcinoma: However, LT has gained a new indication in the BCLC 2022 update; patients with intermediate-stage (BCLC-B) with well-defined HCC nodules should be considered for LT if they meet the institution’s ‘Extended Liver Transplant criteria’ (usually based on size or AFP levels) [5].